Ainara Soria

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

SEOM clinical guidelines for the treatment of head and neck cancer (2020)

L. Iglesias, J. Lambea, Javier Martínez‐Trufero et al. · Clinical & Translational Oncology · 2021 · 98 citations · Full text

Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial

Ezra E.W. Cohen, Kevin J. Harrington, Christophe Le Tourneau et al. · Annals of Oncology · 2017 · 87 citations

Medicine, Clinical Trials, R/m Hnscc +8

Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040

Kevin J. Harrington, Denis Soulières, Christophe Le Tourneau et al. · JNCI Journal of the National Cancer Institute · 2020 · 37 citations · Full text

A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: Analysis of safety and immunogenicity.

Ana Arance, Jean‐François Baurain, Christof Vulsteke et al. · Journal of Clinical Oncology · 2019 · 33 citations

Immunology, Immunoediting, Resected Melanoma +18